We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

CEPHEID

  Silver Develops, manufactures, and markets molecular systems and tests for institutions to perform sophisticated genetic tes... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Five Methods Evaluated for Constrictive Tuberculous Pericarditis Diagnosis

By LabMedica International staff writers
Posted on 24 May 2022
Print article
Image: Photomicrograph from a biopsy specimen of the pericardium shows chronic granulomatous pericarditis with caseous necrosis suggestive of tuberculous pericarditis (Photo courtesy of Western Michigan University Homer Stryker MD School of Medicine)
Image: Photomicrograph from a biopsy specimen of the pericardium shows chronic granulomatous pericarditis with caseous necrosis suggestive of tuberculous pericarditis (Photo courtesy of Western Michigan University Homer Stryker MD School of Medicine)

Constrictive pericarditis is a rare and serious disease that accounts for approximately 0.5%–2% of all heart diseases. It results in decreased pericardial compliance and can severely affect the diastolic filling function of the heart, mainly as a symptom of right heart failure, such as multiple plasma chamber effusions and edema.

Constrictive pericarditis has a poor prognosis, and pericardiectomy is the primary treatment of choice. It has several etiologies, including infection (e.g., tuberculosis [MTB], viral infection, and bacterial infection), malignancy, or radiation therapy. MTB is the most common etiology of constrictive pericarditis in developing countries.

Clinical Diagnosticians at the Zhejiang University School of Medicine (Hangzhou, China) reviewed the case histories of patients with suspected constrictive tuberculous pericarditis (TBP) hospitalized between June 1, 2019 and June 31, 2021, who underwent five tests using pericardial tissue. Fresh, diseased pericardial tissue collected during pericardial dissection was used to perform the five tests. A total of 69 patients were included.

Ground pericardial tissue specimens were centrifuged at 3000 g for approximately 15 minutes. The treated deposits were examined by smear microscopy using Auramine O fluorescent dye and stained with Ziehl–Neelsen for confirmation (AFB). Lowenstein–Jensen solid medium and liquid culture medium BACTEC MGIT 960 Mycobacteria Culture System (BD Diagnostic Systems, Sparks, MD, USA) were used for MTB culture.

The CapitalBio Mycobacterium RT-PCR detection kit (CapitalBio Technology Inc., Beijing, China) provided simultaneous screening of MTB and nontuberculous mycobacteria (NTM) infections. It employs duplex fluorescence RT-PCR and TaqMan probe technology to detect both MTB and NTM infections in one test. The Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA, USA) was also included for comparision. Histological sections were subjected to pathological examination and anti-acid staining by an experienced pathology professional.

The investigators reported that the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and AUC of AFB smear were 7.3%, 100.0%, 100.0%, 21.5%, and 0.54, respectively. Those of culture were 23.6%, 100.0%, 100.0%, 25.0%, and 0.62, respectively. Those of Xpert MTB/RIF were 52.7%, 100.0%, 100.0%, 35.0%, and 0.76, respectively. Those of CapitalBio assay were 50.9%, 100.0%, 100.0%, 34.2%, and 0.75, respectively. Those of pathology were 92.7%, 92.9%, 98.1%, 76.5%, and 0.93, respectively.

The authors concluded that the diagnosis of constrictive TBP remains challenging. The validity of AFB smear and MTB culture using pericardial tissues remains low. NAATs can provide diagnostic efficacy for TBP, but the efficacy is moderate. The CapitalBio assay and Xpert MTB/RIF could be considered similar for diagnosing TBP. The role of pathology in the diagnosis of constrictive TBP cannot be ignored, considering that pathology showed the best diagnostic accuracy among the five tests. The diagnostic accuracy of the same test is similar in acute or subacute TBP and chronic TBP. The study was published on April 13, 2022 in the International Journal of Infectious Diseases.

Related Links:
Zhejiang University School of Medicine 
BD Diagnostic Systems
CapitalBio Technology Inc
Cepheid

Automated ELISA-IFA-BLOT Processor AP 22
New
Platinum Supplier
Hormonal Test
Endocrine Array
New
Automatic Specific Protein Analyzer
PA 900
New
WBC Analyzer
HemoCue WBC System

Print article

Channels

Molecular Diagnostics

view channel
Image: A new method reliably detects protein changes in blood that are typical of Parkinson`s disease (Photo courtesy of Pexels)

First-Ever Blood Test Detects Parkinson’s Disease

Until now, the diagnosis of Parkinson's disease has been based primarily on typical movement disorders such as muscle stiffness, slower movements and shaking. However, the disease starts up to 20 years... Read more

Industry

view channel
Image: Fujirebio has acquired ADx NeuroSciences for 40 million Euros (Photo courtesy of Pexels)

Fujirebio Acquires ADx NeuroSciences to Speed Development of Neurodegenerative Diseases Diagnostic Tests

Fujirebio Holdings, Inc. (Tokyo, Japan) has announced the acquisition of ADx NeuroSciences (Gent, Belgium) for EUR 40 million in a deal that is expected to close in July 2022, pending the satisfaction... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.